文献速递老年综合评估衰弱、肌少症与跌倒多重用药

SPRINT研究中社区老年人强化降压的个体化净获益

Individualized Net Benefit of Intensive Blood Pressure Lowering Among Community-Dwelling Older Adults in SPRINT.
PubMed 文献 · J Am Geriatr Soc · 2025-02-18

该研究基于SPRINT试验中5143例≥65岁社区老年人,用Cox模型预测强化降压(收缩压<120 vs <140 mm Hg)对死亡、心血管、认知结局及严重不良事件的绝对风险差,结合模拟偏好权重计算个体化净获益。结果显示,当获益权重远高于危害时,中位净获益为4个百分点(IQR 3-6),100%参与者净获益为正;当获益与危害权重相近时,中位净获益为1个百分点(IQR 0-2),85%为正。高龄和衰弱者净获益更大,多重用药者在获益权重高时净获益更大(p<0.001)。

要点

  • 多数社区老年高血压患者强化降压至<120 mm Hg的个体化净获益为正。
  • 净获益大小随风险估计和偏好权重变化,获益权重越高净获益越大。
  • 高龄、衰弱及多重用药者净获益可能更大,但需结合偏好个体化决策。

核心结论

  • 在SPRINT社区老年高血压患者中,几乎所有人净获益均支持收缩压目标<120 mm Hg。
  • 净获益的幅度因估计风险和模拟偏好不同而变化。

研究设计与样本

  • 基于SPRINT试验中5143例年龄≥65岁的社区居住老年人进行二次分析。
  • 采用内部验证的Cox模型预测强化降压(收缩压<120 vs <140 mm Hg)对各结局的绝对风险差,并用模拟偏好权重合成个体化净获益。

主要发现

  • 当模拟偏好认为降压获益(减少死亡、心血管事件和认知损害)远重于治疗相关危害时,中位净获益为4个百分点(IQR 3-6),100%参与者净获益为正。
  • 当模拟获益与危害重要性相似时,中位净获益为1个百分点(IQR 0-2),85%参与者净获益为正。
  • 高龄和衰弱参与者在两种模拟中尽管经历更多危害,但强化降压净获益更大。
  • 多重用药参与者在获益远重于危害的模拟中净获益更大(p<0.001)。

关键数值与推荐

  • 强化降压目标为收缩压<120 mm Hg,对照目标为<140 mm Hg。
  • 净获益以加权风险差之和表示,偏好权重通过模拟设定。
  • 高龄定义为65-74岁 vs ≥75岁;衰弱状态采用SPRINT衍生的fit、less fit和frail分类;多重用药定义为≥5种药物。

临床怎么用

  • 对社区老年高血压患者,强化降压至<120 mm Hg在多数情况下净获益为正,可考虑作为个体化决策选项。
  • 决策时应结合患者偏好(对获益与危害的重视程度)及风险估计,高龄、衰弱和多重用药者可能净获益更大但需关注危害。

局限性

  • 研究为基于SPRINT试验的二次分析,结果外推需谨慎。
  • 净获益计算依赖模拟偏好权重,可能不能完全反映真实患者偏好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal blood pressure (BP) target for older adults with hypertension remains controversial, particularly among those with advanced age, frailty, or polypharmacy. This study estimated the individualized net benefit of intensive BP lowering among community-dwelling older adults in the Systolic Blood Pressure Intervention Trial (SPRINT). METHODS: Among 5143 SPRINT participants age ≥ 65 years, Cox models were internally validated to predict an absolute difference in risk between treating to a systolic BP target of < 120 versus < 140 mm Hg for all-cause death, cardiovascular outcomes, cognitive outcomes, and serious adverse events. Treatment effects were combined using simulated preference weights into individualized net benefits, representing the weighted sum of risk differences across outcomes. Net benefits were compared across categories of age (65-74 vs. ≥ 75 years), SPRINT-derived frailty status (fit, less fit, and frail), and polypharmacy (≥ 5 medications). RESULTS: When simulating preferences for participants who view the benefits of BP lowering (reduction in death, cardiovascular events, and cognitive impairment) as much more important than treatment-related harms (e.g., acute kidney injury and syncope), the median net benefit from intensive BP lowering was 4 percentage points (IQR: 3-6), and 100% had a positive net benefit favoring intensive BP lowering. When simulating benefits and harms to have similar, intermediate importance, the median net benefit was 1 percentage point (IQR: 0-2), and 85% had a positive net benefit. Participants with advanced age and frailty had greater net benefits from intensive BP lowering despite experiencing more harm in both simulations, and those with polypharmacy had greater net benefits when benefits were viewed as much more important than harms (p < 0.001 for all comparisons). CONCLUSIONS: Among community-dwelling older adults with hypertension in SPRINT, almost all participants had a net benefit that favored a systolic BP target of < 120 mm Hg, but the magnitude of net benefit varied according to estimated risks and simulated preferences.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Jamshidian MS, Scherzer R, Estrella MM, et al. Individualized Net Benefit of Intensive Blood Pressure Lowering Among Community-Dwelling Older Adults in SPRINT. J Am Geriatr Soc. 2025. PMID: 39967308. doi:10.1111/jgs.19395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。